Emmaus Life Sciences Inc
OTC:EMMA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Emmaus Life Sciences Inc
Cash Interest Paid
Emmaus Life Sciences Inc
Cash Interest Paid Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash Interest Paid | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Emmaus Life Sciences Inc
OTC:EMMA
|
Cash Interest Paid
$2.5m
|
CAGR 3-Years
24%
|
CAGR 5-Years
11%
|
CAGR 10-Years
N/A
|
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Cash Interest Paid
$3.8B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Cash Interest Paid
$2.1B
|
CAGR 3-Years
14%
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
|
|
|
Pfizer Inc
NYSE:PFE
|
Cash Interest Paid
$2.7B
|
CAGR 3-Years
24%
|
CAGR 5-Years
11%
|
CAGR 10-Years
8%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Cash Interest Paid
$1.3B
|
CAGR 3-Years
12%
|
CAGR 5-Years
10%
|
CAGR 10-Years
7%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Cash Interest Paid
$633m
|
CAGR 3-Years
25%
|
CAGR 5-Years
13%
|
CAGR 10-Years
17%
|
|
Emmaus Life Sciences Inc
Glance View
Emmaus Life Sciences, Inc. operates as a biopharmaceutical company. The company is headquartered in Torrance, California and currently employs 58 full-time employees. The company went IPO on 2000-05-09. The Company’s lead product, Endari was approved by the United States Food and Drug Administration (FDA) to reduce the acute complications of sickle cell disease (SCD) in adult and pediatric patients five years of age and older. Endari has received Orphan Drug designation from the FDA and Orphan Medicinal designation from the European Commission. Endari’s safety profile was like the placebo and Endari was well-tolerated in pediatric and adult patients alike. Its product pipeline includes ELS001/ELS007, ELS004, ELS005, ELS003 and ELS002. The Company’s subsidiaries include EMI Holding, Inc., Emmaus Medical, Inc., Emmaus Medical Japan, Inc., Newfield Nutrition Corporation, Emmaus Medical Europe Limited, Emmaus Medical Europe Limited and Emmaus Life Sciences, Co. Ltd.
See Also
What is Emmaus Life Sciences Inc's Cash Interest Paid?
Cash Interest Paid
2.5m
USD
Based on the financial report for Dec 31, 2025, Emmaus Life Sciences Inc's Cash Interest Paid amounts to 2.5m USD.
What is Emmaus Life Sciences Inc's Cash Interest Paid growth rate?
Cash Interest Paid CAGR 5Y
11%
Over the last year, the Cash Interest Paid growth was 13%. The average annual Cash Interest Paid growth rates for Emmaus Life Sciences Inc have been 24% over the past three years , 11% over the past five years .
